Medicinova Stock Alpha and Beta Analysis
| MNOV Stock | USD 2.00 0.05 2.56% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as MediciNova. It also helps investors analyze the systematic and unsystematic risks associated with investing in MediciNova over a specified time horizon. Remember, high MediciNova's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to MediciNova's market risk premium analysis include:
Beta (2.52) | Alpha 1.19 | Risk 8.56 | Sharpe Ratio 0.12 | Expected Return 1.04 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
MediciNova |
MediciNova Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. MediciNova market risk premium is the additional return an investor will receive from holding MediciNova long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in MediciNova. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate MediciNova's performance over market.| α | 1.19 | β | -2.52 |
MediciNova expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of MediciNova's Buy-and-hold return. Our buy-and-hold chart shows how MediciNova performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.MediciNova Market Price Analysis
Market price analysis indicators help investors to evaluate how MediciNova stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading MediciNova shares will generate the highest return on investment. By understating and applying MediciNova stock market price indicators, traders can identify MediciNova position entry and exit signals to maximize returns.
MediciNova Return and Market Media
The median price of MediciNova for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 1.8 with a coefficient of variation of 13.48. The daily time series for the period is distributed with a sample standard deviation of 0.24, arithmetic mean of 1.76, and mean deviation of 0.18. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | MediciNova Inc. Poised for Advancement Among Biotech Peers | 08/28/2024 |
2 | MediciNova Receives Notice of Allowance from United States Patent and Trademark Office forNew Patent Covering MN-166 for the Post-COVID Condition | 08/29/2024 |
3 | MediciNova Announces Acceptance of Abstract Regarding MN-166 in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS Meeting | 09/03/2024 |
4 | MediciNova Announces Abstract Regarding MN-166 in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS MND | 09/09/2024 |
5 | MediciNova Receives New Coverage from Analysts at StockNews.com | 09/13/2024 |
6 | MediciNova Stock Price Crosses Above Two Hundred Day Moving Average of 1.42 - MarketBeat | 09/27/2024 |
7 | Acquisition by Nagao Hideki of 20000 shares of MediciNova at 1.34 subject to Rule 16b-3 | 10/04/2024 |
8 | MediciNova shareholders have endured a 73 percent loss from investing in the stock five years ago | 10/07/2024 |
9 | 75 Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space DelveInsight | 11/13/2024 |
10 | MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders | 11/19/2024 |
About MediciNova Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including MediciNova or other stocks. Alpha measures the amount that position in MediciNova has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Days Sales Outstanding | 328.79 | 292.26 | PTB Ratio | 1.18 | 1.63 |
MediciNova Upcoming Company Events
As portrayed in its financial statements, the presentation of MediciNova's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, MediciNova's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of MediciNova's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of MediciNova. Please utilize our Beneish M Score to check the likelihood of MediciNova's management manipulating its earnings.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with MediciNova
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for MediciNova Stock Analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.